Testes‑specific protease 50 as an independent risk factor for poor prognosis in patients with non‑small cell lung cancer

Qiao,Wen‑Liang; Shi,Bo‑Wen; Han,Yu‑Dong; Tang,Hua‑Mei; Lin,Jun; Hu,Hai‑Yang; Lin,Qiang

doi:10.3892/ol.2018.8387

Testes‑specific protease 50 as an independent risk factor for poor prognosis in patients with non‑small cell lung cancer

Authors:
- Wen‑Liang Qiao
- Bo‑Wen Shi
- Yu‑Dong Han
- Hua‑Mei Tang
- Jun Lin
- Hai‑Yang Hu
- Qiang Lin
View Affiliations

Affiliations: Department of Thoracic Surgery, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, P.R. China, Department of Pathology, Shanghai First People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, P.R. China
Published online on: March 29, 2018 https://doi.org/10.3892/ol.2018.8387
Pages: 8796-8804

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Testes‑specific protease 50 (TSP50) is normally expressed in the testes and is overexpressed in various types of human cancers, including breast cancer, colorectal carcinoma and laryngocarcinoma. However, little has been reported on the association between TSP50 and non‑small cell lung cancer (NSCLC). The present study aimed to detect TSP50 expression in 198 strict follow‑up cases of paired NSCLC and 15 cases of normal lung parenchymal specimens using immunohistochemical staining. The expression levels of TSP50 were then correlated with the clinicopathological factors of NSCLC to assess its potential diagnostic and prognostic value. The relationship between TSP50 expression and the clinicopathological parameters of NSCLC was evaluated using χ2 and Fisher's exact tests. Survival rates for the overall population (n=198) were calculated using the Kaplan‑Meier method, and univariate and multivariate analyses were performed using the Cox's proportional hazards regression model. P<0.05 was considered to indicate a statistically significant difference. The expression of TSP50 was significantly increased in NSCLC tissue compared with in adjacent non‑tumor or normal lung parenchymal tissue (P<0.001). A significant association was revealed between high expression levels of TSP50 and clinicopathological characteristics including tumor differentiation (P=0.012), late tumor status (P=0.004) and late tumor node metastasis stage (P=0.026), as well as a reduced disease free survival (P=0.009) and overall survival rate (P=0.002) in all patients with NSCLC. Multivariate analyses demonstrated that high TSP50 expression in tumor tissues was significantly associated with a shorter disease‑free survival rate [hazard ratio (HR) =1.590, 95% confidence interval (CI): 1.035‑2.441], and with a shorter overall survival rate (HR=1.814; 95% CI: 1.156‑2.846). In conclusion, the present data demonstrated that increased TSP50 protein expression may be a potential predictor of early recurrence and poor prognosis in NSCLC, and that TSP50 expression levels possess the potential to be used as a biomarker and therapeutic target for the treatment of patients with NSCLC.

View Figures

View References

1	Herbst RS, Heymach JV and Lippman SM: Lung Cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med. 350:379–392. 2004. View Article : Google Scholar : PubMed/NCBI
4	Goldstraw P: The 7th edition of TNM in lung cancer: What now? J Thorac Oncol. 4:671–673. 2009. View Article : Google Scholar : PubMed/NCBI
5	Yuan LM, Shan JD, De Risi D, Broome J, Lovecchio J, Gal D, Vinciguerra V and Xu HP: Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. Cancer Res. 59:3215–3221. 1999.PubMed/NCBI
6	Shan J, Yuan L, Xiao Q, Chiorazzi N, Budman D, Teichberg S and Xu HP: A possible protease in human testes, is activated in breast cancer epithelial cells1. Cancer Res. 62:290–294. 2002.PubMed/NCBI
7	Xu H, Shan J, Jurukovski V, Yuan L, Li J and Tian K: TSP50 encodes a testis-specific protease and is negatively regulated by p53. Cancer Res. 67:1239–1245. 2007. View Article : Google Scholar : PubMed/NCBI
8	Song ZB, Bao YL, Zhang Y, Mi XG, Wu P, Wu Y, Yu CL, Sun Y, Zheng LH and Huang YX: Testes-specific protease 50 (TSP50) promotes cell proliferation through the activation of the nuclear factor κB (NF-κB) signalling pathway. Biochem J. 436:457–467. 2011. View Article : Google Scholar : PubMed/NCBI
9	Song ZB, Ni JS, Wu P, Bao YL, Liu T, Li M, Fan C, Zhang WJ, Sun LG, Huang YX and Li YX: Testes-specific protease 50 promotes cell invasion and metastasis by increasing NF-kappaB-dependent matrix metalloproteinase-9 expression. Cell Death Dis. 6:e17032015. View Article : Google Scholar : PubMed/NCBI
10	Zheng L, Xie G, Duan G, Yan X and Li Q: High Expression of Testes-specific protease 50 is associated with poor prognosis in colorectal carcinoma. PLoS One. 6:e222032011. View Article : Google Scholar : PubMed/NCBI
11	Liu F, Cao Q, Liu N, Li C, You C, Liu C, Xue L and Luo R: Overexpression of testes-specific protease 50 (TSP50) predicts poor prognosis in patients with gastric cancer. Gastroenterol Res Pract. 2014:4982462014. View Article : Google Scholar : PubMed/NCBI
12	Yuan J, Wu C, Huang M, Zhou J, Ben W and Zhang G: TSP50 depends on its threonine protease activity and its interactions with TNF-α-induced NF-κB for its role in human cervical tumorigenesis. Cell Biochem Biophys. 71:891–896. 2015. View Article : Google Scholar : PubMed/NCBI
13	Maggiore C, Mulè A, Fadda G, Rossi ED, Lauriola L, Vecchio FM and Capelli A: Histological classification of lung cancer. Rays. 29:353–355. 2004.PubMed/NCBI
14	Wang M, Bao YL, Wu Y, Yu CL, Meng XY, Huang YX, Sun Y, Zheng LH and Li YX: Basic FGF Downregulates TSP50 expression via the ERK/Sp1 Pathway. J Cell Biochem. 111:75–81. 2010. View Article : Google Scholar : PubMed/NCBI
15	Song ZB, Liu B, Li YY, Wu P, Bao YL, Huang YX, Wu Y, Sun LG, Yu CL, Sun Y, et al: The catalytic triad of testes-specific protease 50 (TSP50) is essential for its function in cell proliferation. Cell Signal. 26:2266–2275. 2014. View Article : Google Scholar : PubMed/NCBI
16	Wei J, Liu Y, Yang S, Xu J, Kong H, Han B, Bao Y, Wu Y, Yin W, Li W, et al: Screening of single-chain variable fragments against TSP50 from a phage display antibody library and their expression as soluble proteins. J Biomol Screen. 11:546–552. 2006. View Article : Google Scholar : PubMed/NCBI
17	Liu YL and Sun YN: Down-regulation of testes-specific protease 50 induces apoptosis in human laryngocarcinoma HEp2 cells in a NF-κB-mediated pathway. Mol Biol. 41:7743–7747. 2014.
18	Kosaka-Suzuki N, Suzuki T, Pugacheva EM, Vostrov AA, Morse HC III, Loukinov D and Lobanenkov V: Transcription factor BORIS (Brother of the Regulator of Imprinted Sites) directly induces expression of a cancer-testis antigen, TSP50, through regulated binding of BORIS to the Promoter. J Biol Chem. 286:27378–27388. 2011. View Article : Google Scholar : PubMed/NCBI
19	Cheng YH, Wong EW and Cheng CY: Cancer/testis, (CT) antigens, carcinogenesis and spermatogenesis. Spermatogenesis. 1:209–220. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kim YD, Park HR, Song MH, Shin DH, Lee CH, Lee MK and Lee SY: Pattern of cancer/testis antigen expression in lung cancer patients. Int J Mol Med. 29:656–662. 2012. View Article : Google Scholar : PubMed/NCBI
21	Grah JJ, Katalinic D, Juretic A, Santek F and Samarzija M: Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer. Tumori. 100:60–68. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zhang XP: Depression of testes-specific protease 50 (TSP50) inhibits cell proliferation and induces apoptosis in laryngocarcinoma. Tumour Biol. 35:10781–10788. 2014. View Article : Google Scholar : PubMed/NCBI
23	Li YY, Bao YL, Song ZB, Sun LG, Wu P, Zhang Y, Fan C, Huang YX, Wu Y, Yu CL, et al: The threonine protease activity of testes-specific protease 50 (TSP50) is essential for its function in cell proliferation. PLoS One. 7:e350302012. View Article : Google Scholar : PubMed/NCBI
24	Gjerstorff MF, Andersen MH and Ditzel HJ: Oncogenic cancer/testis antigens: Prime candidates for immunotherapy. Oncotarget. 6:15772–15787. 2015. View Article : Google Scholar : PubMed/NCBI
25	Zhou L, Bao YL, Zhang Y, Wu Y, Yu CL, Huang YX, Sun Y, Zheng LH and Li YX: Knockdown of TSP50 inhibits cell proliferation and induces apoptosis in P19 cells. IUBMB Life. 62:825–832. 2010. View Article : Google Scholar : PubMed/NCBI
26	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–94. 2008. View Article : Google Scholar : PubMed/NCBI
27	Mostafa AA and Morris DG: Immunotherapy for lung cancer: Has it finally arrived? Front Oncol. 4:2882014. View Article : Google Scholar : PubMed/NCBI